goglides.dev
ResearchFinanceTechCompaniesDiscussion
Search
Sign inJoin
goglidesgoglides.devSocial learning for Finance and Tech.
TermsPrivacyDisclaimerModerationAcceptable UseDMCAContact
Company / Finance

ADMA Biologics Inc

ADMA · UNKNOWN

ADMA is profitable and ASCENIV is still growing, but Q1 2026 reset the story: standard IG pricing pressure, distributor timing, BIVIGAM weakness, and long-term guidance withdrawal turned 2026 into a proof year.

FollowAdd to WatchlistAsk Question
ADMAADMA Biologics IncBiopharmaceuticalsCoverage BootstrapImmunologyNASDAQ
OverviewFinancialsResearchTimelineCompareValuationScorecardDiscussion
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue